Background: T cell receptor beta (TCRβ) immune repertoire analysis by next-generation sequencing
is emerging as a valuable tool for research studies of the tumor microenvironment
and potential immune responses to cancer immunotherapy. Here we describe an AmpliSeqTM-based TCRβ sequencing assay that leverages the long read capability of the Ion 530TM chip to provide coverage of all three complimentary determining region (CDR) domains
of the human TCRβ chain. We demonstrate use of the assay to evaluate tumor-infiltrating
T cell repertoire features, monitor manufacture of therapeutic T cells, and discover
TRBV gene allele polymorphisms that may predict autoimmune disease or immune-mediated
adverse events.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
P02.10
Identification
Copyright
© 2018 Published by Elsevier Inc.
